In short
This article discusses the clinical trials of UX701, an innovative gene therapy using Adeno-Associated Viral Vector Serotype 9 Encoding Human ATP7B for the treatment of Wilson Disease. The study aims to evaluate the safety and efficacy of this groundbreaking approach in managing copper metabolism in adult patients with Wilson Disease. We'll explore the trial design, eligibility criteria, and potential outcomes of this promising treatment.
At a glance
- Study Drug
- UX701 (Adeno-Associated Viral Vector Serotype 9 Encoding Human ATP7B)
- Condition
- Wilson Disease
- Study Design
- Multicenter, seamless, adaptive Phase 1/2/3 clinical study
- Primary Objectives
- Evaluate safety, select optimal dose, assess effect on copper regulation, determine reduction in standard-of-care medication
- Key Eligibility Criteria
- Adults ≥18 years, confirmed Wilson Disease diagnosis, stable on current therapy for ≥12 months
- Study Duration
- 52 weeks initial follow-up, followed by long-term follow-up up to 4 years
- Primary Endpoints
- Change in 24-hour urinary copper concentration, percent reduction in standard-of-care medication
- Secondary Endpoints
- Changes in ceruloplasmin activity, patient-reported outcomes, liver copper concentration
What is UX701?
UX701 is an experimental gene therapy being developed for the treatment of Wilson Disease. It is also known as ADENO-ASSOCIATED VIRAL VECTOR SEROTYPE 9 ENCODING HUMAN ATP7B or AAV9ATP7B-MBD456. This therapy is designed to introduce a functional copy of the ATP7B gene into the body, which is responsible for copper metabolism.
How does UX701 work?
UX701 uses a modified virus called adeno-associated virus serotype 9 (AAV9) to deliver a healthy copy of the ATP7B gene to liver cells. The ATP7B gene provides instructions for making a protein that helps regulate copper levels in the body. In people with Wilson Disease, this gene is faulty, leading to copper accumulation. By introducing a working copy of the gene, UX701 aims to restore normal copper metabolism.
What is Wilson Disease?
Wilson Disease is a rare genetic disorder that affects copper metabolism. People with this condition cannot properly remove excess copper from their body, leading to its accumulation in various organs, particularly the liver and brain. This can cause a wide range of symptoms, including liver disease, neurological problems, and psychiatric issues.
Clinical Trial Details
A clinical trial is currently underway to evaluate the safety and effectiveness of UX701 for Wilson Disease. This study is divided into several stages:
- Stage 1 (Phase 1/2): This initial stage aims to assess the safety of UX701 and determine the best dose for further testing.
- Stage 2 (Phase 3): This stage will compare UX701 to a placebo to evaluate its effectiveness in treating Wilson Disease.
- Stage 3: This final stage will provide long-term follow-up to assess the ongoing safety and benefits of UX701.
Eligibility Criteria
To participate in this study, patients must meet certain criteria, including:
- Be 18 years or older
- Have a confirmed diagnosis of Wilson Disease based on genetic testing
- Be on stable copper chelator and/or zinc therapy for at least 12 months
- Have stable urinary copper levels
- Be willing to follow a low-copper diet
There are also several exclusion criteria, such as a history of liver transplant, advanced liver disease, or certain other medical conditions.
Potential Benefits
The potential benefits of UX701 therapy include:
- Improved copper regulation in the body
- Reduced need for standard-of-care medications
- Improved liver function and overall health
- Better quality of life for patients with Wilson Disease
Safety Considerations
As with any experimental treatment, there are potential risks and side effects. The clinical trial is designed to carefully monitor participants for any adverse events. Some safety measures include:
- Regular monitoring of liver function and copper levels
- Use of prophylactic oral corticosteroids to prevent potential liver-related side effects
- Long-term follow-up to assess ongoing safety
It's important to note that UX701 is still in the experimental stage, and its long-term safety and effectiveness are not yet fully known. Patients considering participation in this clinical trial should discuss the potential risks and benefits with their healthcare provider.